文献速递细菌感染、耐药与抗菌药物

基于探针熔解曲线的新型检测方法用于表征生殖支原体对氟喹诺酮类耐药

Novel probe-based melting curve assays for the characterization of fluoroquinolone resistance in Mycoplasma genitalium.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

本研究开发了两种概念验证性分子检测方法,用于检测生殖支原体并表征与氟喹诺酮类敏感性密切相关的野生型parC序列。用分子信标和双杂交探针检测227份生殖支原体阳性样本,其中143/227(63%)可检测生殖支原体并表征氟喹诺酮类敏感性,结果与Sanger测序100%一致;低载量样本的表征能力下降。

要点

  • 新型分子信标与双杂交探针检测可在143/227(63%)样本中表征氟喹诺酮类敏感性。
  • 检测结果与金标准Sanger测序100%一致,并可区分野生型parC与已知或疑似有临床意义的parC突变。
  • 低生殖支原体载量样本中,成功表征氟喹诺酮类敏感性与耐药的能力下降。

核心结论

  • 这些概念验证性检测方法在改善个体化治疗和合理化生殖支原体感染的治愈检测方面有相当大的潜力。
  • 对多达三分之二的病例启动个体化治疗,将增强对这一难治病原体的抗菌药物管理。

研究设计与样本

  • 研究为概念验证性分子检测开发研究,开发了两种聚焦于检测生殖支原体及表征与氟喹诺酮类敏感性密切相关的野生型parC序列的分子检测。
  • 共筛查227份生殖支原体阳性样本,使用新型分子信标和双杂交探针检测。
  • 以Sanger测序作为金标准进行对照。

主要发现

  • 两种检测可在143/227(63%)份样本中检测生殖支原体并表征氟喹诺酮类敏感性,依据为熔解峰温度的明显差异。
  • 分子检测结果与金标准Sanger测序100%一致。
  • 野生型parC序列可与携带已知或疑似有临床意义parC突变的生殖支原体样本相区分。
  • 在低生殖支原体载量样本中,检测成功表征氟喹诺酮类敏感性与耐药的能力下降。

临床怎么用

  • 作者认为这些概念验证性检测方法在改善个体化治疗和合理化生殖支原体感染的治愈检测方面有相当大的潜力。
  • 作者指出,对多达三分之二的病例启动个体化治疗将增强对这一难治病原体的抗菌药物管理。

局限性

  • 这些检测为概念验证性检测。
  • 在低生殖支原体载量样本中,检测成功表征氟喹诺酮类敏感性与耐药的能力下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mycoplasma genitalium infection is a sexually transmitted infection that has rapidly become resistant to mainstay treatments. While individualized treatment approaches have been recommended and adopted for macrolides, individualized therapy for fluoroquinolones has not yet been explored, due to a lack of commercial molecular assays and a lack of confidence in specific mutations associated with resistance. In another recent study, we defined a clear role and diagnostic utility in focusing on the absence of resistance mutations to inform microbial cure with fluoroquinolone antimicrobials. METHODS: We developed two proof-of-concept molecular tests that focus on detection of M. genitalium and characterization of WT parC sequences that are strongly linked to fluoroquinolone susceptibility. RESULTS: We screened a total of 227 M. genitalium-positive samples using novel molecular beacon and dual hybridization probe assays. These assays were able to detect M. genitalium and characterize fluoroquinolone susceptibility in 143/227 (63%) samples, based on clear differences in melting peak temperatures. The results of these molecular assays were in 100% agreement with 'gold standard' Sanger sequencing. Additionally, WT parC sequences were readily distinguished from M. genitalium samples harbouring parC mutations of known or suspected clinical significance. The ability of the assays to successfully characterize fluoroquinolone susceptibility and resistance was reduced in low M. genitalium load samples. CONCLUSIONS: These proof-of-concept assays have considerable potential to improve individualized treatment approaches and rationalize tests of cure for M. genitalium infection. The ability to initiate individualized treatment in up to two-thirds of cases will enhance antimicrobial stewardship for this challenging pathogen.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Tickner JA, Bradshaw CS, Murray GL, et al. Novel probe-based melting curve assays for the characterization of fluoroquinolone resistance in Mycoplasma genitalium. J Antimicrob Chemother. 2022. PMID: 35352120. doi:10.1093/jac/dkac097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。